Literature DB >> 18061971

Systemic lupus erythematosus in a patient treated with etanercept for polyarticular juvenile rheumatoid arthritis.

Sharon Bout-Tabaku, Rafael Rivas-Chacon, Ricardo Restrepo.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18061971

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


× No keyword cloud information.
  7 in total

1.  Mechanisms of tumor necrosis factor α antagonist-induced lupus in a murine model.

Authors:  Yuan Xu; Haoyang Zhuang; Shuhong Han; Chao Liu; Hai Wang; Clayton E Mathews; John Massini; Lijun Yang; Westley H Reeves
Journal:  Arthritis Rheumatol       Date:  2015-01       Impact factor: 10.995

Review 2.  The development and assessment of biological treatments for children.

Authors:  Eve M D Smith; Helen E Foster; Michael W Beresford
Journal:  Br J Clin Pharmacol       Date:  2015-03       Impact factor: 4.335

Review 3.  The safety profile of biologic therapies for juvenile idiopathic arthritis.

Authors:  Philip J Hashkes; Yosef Uziel; Ronald M Laxer
Journal:  Nat Rev Rheumatol       Date:  2010-08-31       Impact factor: 20.543

4.  [Secukinumab-induced subacute-cutaneous lupus erythematosus].

Authors:  C Wehrmann; W Sondermann; A Körber
Journal:  Hautarzt       Date:  2018-01       Impact factor: 0.751

5.  TNFα inhibitor induced lupus-like syndrome (TAILS) in a patient with IBD.

Authors:  A Lupu; C Tieranu; C L Constantinescu; M Diculescu
Journal:  Curr Health Sci J       Date:  2014-12-14

6.  Challenges in the management of juvenile idiopathic arthritis with etanercept.

Authors:  Clare E Pain; Liza J McCann
Journal:  Biologics       Date:  2009-07-13

Review 7.  Clinical utility of etanercept in the treatment of arthritides in children and adolescents.

Authors:  Robin K Dore
Journal:  Adolesc Health Med Ther       Date:  2014-03-26
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.